Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 34 of 114

  1. DAC-HAAG-02

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. DANTE/FLOT8

    The George Institute

    locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach

    phase 3 small molecule active

    1 trial

  3. DANUBE/D419BC00001

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

  4. DAPA-PedHKD

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pediatric Hereditary Kidney Diseases

    phase 3 small molecule active

    1 trial

  5. DAPAGLIFLOZIN, PLACEBO

    Disc Medicine

    Hypomagnesemia due to HNF1beta mutation

    phase 3 small molecule active

    1 trial

  6. DAPAGLIFLOZIN, PLACEBO DE DAPAGLIFLOZIN 10 mg

    Pari Pharma GmbH

    Cardiac failure

    phase 3 small molecule active

    1 trial

  7. DARAXONRASIB (RMC-6236), DARAXONRASIB (RMC-6236)

    Revolution Medicines

    Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  8. DAUNORUBICIN for Favorable-intermediate-risk Acu…

    Fondazione Telethon ETS

    Favorable-intermediate-risk Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  9. DAY101-002

    Lacuna Pharma Pty Ltd

    Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

    phase 3 small molecule active

    1 trial

  10. DBV712

    DBV Technologies

    Allergy, Peanut

    phase 3 small molecule active

    1 trial

  11. DC 06/02

    Takeda

    Adrenal Insufficiency

    phase 3 small molecule completed

    1 trial

  12. DCC-2618-03-002

    Lacuna Pharma Pty Ltd

    Patients with Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  13. DCC-3014-03-001

    Lacuna Pharma Pty Ltd

    Tenosynovial Giant Cell Tumor

    phase 3 small molecule active

    1 trial

  14. DCCR

    SOLENO THERAPEUTICS INC

    Prader-Willi Syndrome

    phase 3 small molecule active

    4 trials

  15. DCR-PHXC-301

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 3 other active

    1 trial

  16. DCS (D-Cycloserine ) + Prolonged Imaginal Exposure

    United Therapeutics Europe Ltd

    Post Traumatic Stress Disorder

    phase 3 small molecule completed

    1 trial

  17. DEN-303

    Takeda

    Dengue Fever

    phase 3 mab completed

    1 trial

  18. DESTINYEndometrial01

    AstraZeneca AB

    HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  19. DEXAMETHASONE for Onco-hematology

    Pari Pharma GmbH

    Onco-hematology

    phase 3 small molecule active

    1 trial

  20. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  21. DHM/EPH/01/2022

    Lacuna Pharma Pty Ltd

    Menopause, sleep disorders in the postmenopausal period

    phase 3 small molecule active

    1 trial

  22. DICES

    COLLEGIUM PHARMACEUTICAL, INC

    Breast cancer

    phase 3 other active

    1 trial

  23. DIDaC/ NVALT35

    Disc Medicine

    Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.

    phase 3 small molecule active

    1 trial

  24. DISC-1459

    Disc Medicine

    Erythropoietic Protoporphyria

    phase 3 small molecule active

    2 trials

  25. DLY201619

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer Stage IIIA

    phase 3 small molecule terminated

    1 trial

  26. DM199-2021-001

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  27. DMT310

    Dermata Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    3 trials

  28. DNL343

    Denali Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    2 trials

  29. DOCETAXEL

    Pfizer Australia Pty Ltd

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  30. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV Infection

    phase 3 small molecule active

    1 trial

  31. DP-10027

    Lacuna Pharma Pty Ltd

    post-operative nausea and vomiting in pediatric patients

    phase 3 small molecule active

    1 trial

  32. DR-1011

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  33. DR-102

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  34. DR-1021

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

  35. DR-1021

    Teva Pharma GmbH

    Healthy

    phase 3 small molecule completed

    1 trial

  36. DR-103

    Teva Pharma GmbH

    Pregnancy Prevention

    phase 3 small molecule completed

    1 trial

  37. DR-104

    Teva Pharma GmbH

    Emergency Contraception

    phase 3 small molecule completed

    1 trial

  38. DR-2011

    Teva Pharma GmbH

    Infertility

    phase 3 small molecule completed

    2 trials

  39. DR-2041a

    Teva Pharma GmbH

    Menopause

    phase 3 small molecule completed

    1 trial

  40. DR-3001

    Teva Pharma GmbH

    Overactive Bladder

    phase 3 small molecule completed

    1 trial

  41. DR-5001

    Teva Pharma GmbH

    Respiratory Tract Diseases

    phase 3 mab completed

    1 trial

  42. DR200091

    Tour Hekla

    Thrombotic episodes in superficial venous malformations in children

    phase 3 small molecule active

    1 trial

  43. DR230005

    Tour Hekla

    Patients with ventilator-associated tracheobronchitis

    phase 3 small molecule active

    1 trial

  44. DR230297

    Tour Hekla

    Acute ischaemic stroke due to basilar artery occlusion.

    phase 3 small molecule active

    1 trial

  45. DR230333

    Tour Hekla

    Intersitial lung disease related to systemic sclerosis

    phase 3 small molecule active

    1 trial

  46. DR240020

    Tour Hekla

    Hypoxemic acute respiratory failure

    phase 3 small molecule active

    1 trial

  47. DS-8201a

    Daiichi Sankyo

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    phase 3 small molecule active

    1 trial

  48. DS1062-328

    Daiichi Sankyo

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.